Fidia Advanced Biopolymers S.r.l.

Fidia S.p.a.

Fidia Farmaceutici S.p.a.

M.u.r.s.t. (italian Ministry for Universities and Scientific and

Jointherapeutics S.r.l.

Genetics Institute, Inc.

Sorin Biomedica S.p.a.

Anika Therapeutics S.r.l.

Fidia Advanced Bioplymers, Srl

M.u.r.s.t. Italian Ministry for Universities and Scientific and Technological Research

M.u.r.s.t. Italian Ministry for Universitites and Scientific and

Italian Ministry for Universities and Scientific and Technological

Fidia Farmaceuti S.p.a.

Fidia Advanced Biopolymer S.r.l.

Glycocore Pharma

Lanfranco Callegaro

Aurelio Romeo

Alessandra Pavesio

Francesco Della Valle

Luca Benedetti

Franco Dorigatti

Davide Renier

Paolo Pallado

Giulio Bianchini

Giovanni Gennari

Susanna Vaccaro

Davide Bellini

Vittorio Crescenzi

Salvatore Caruso

Maurizio Dalle Carbonare

Giovanni Abatangelo

Antonio Giannelli

John Martin Wozney

Howard Seeherman

Silvana Lorenzi

Rebecca Li

Gino Toffano

Daniele Pressato

Andrea Pastorello

Alessandro Negro

Hyun Kim

Marco Radice

David Renier

Marco Baggio

Luigi Nicolais

Anna Maria Zanellato

Devis Galesso

Marco Morra

Luigi Ambrosio

Sergio Di Fede

Paolo Giusti

Anna Taglienti

Maurilio Marcacci

Clara Cassinelli

Ennio Denti

Paola Brun

Massimo Dona'

Michael O'Regan

Annamaria Paparella

Marie Astier

Filippo Biviano

Fabio Giusti

Carlo Soranzo

Paolo Antonio Netti

Ombretta Stanchi

Giorgio Favaro

Umberto Rosa

Valdano Rossi

Antonio Boniolo

Margherita Morpurgo

The invention discloses a functionalised chitosan, or a salt thereof, used in the treatment of pathologies of the respiratory tract or hepatic pathologies, preferably caused by viral infections. It was indeed observed that said functionalised chitosan or salt thereof was able to act as galectin-modulator, modulating in particular galectin-3, and therefore determining a marked reduction in the inflammatory and fibrotic cascade generated by these viral infections. The invention moreover discloses a pharmaceutical composition, as well as a biomaterial, comprising this functionalised chitosan, or a salt thereof.

Use of functionalised chitosan in the treatment of inflammatory/fibrotic pathologies of the respiratory tract and hepatic pathologies

The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

Functionalized hyaluronic acid or a derivative thereof in the treatment of inflammatory states

A neutral salt consisting of a polyaminosaccharide cation and an anion, as well as a procedure for the preparation of the neutral salt and uses thereof as a biomaterial and as an ingredient in pharmaceutical compositions are disclosed. Indeed, said neutral salt has surprisingly exhibited high water-solubility and high purity, the preparation procedure having minimised the content of high-risk contaminants in the final product and reduced reaction and purification times.

Water-soluble polysaccharide derivatives, process for their preparation, and their uses

The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.

Polysaccharide compositions for tissue repair

The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.

Pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers

This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.

Sulphated hyaluronic acid for treating degenerative osteoarthritis

There is described a new non-woven fabric produced with the electrospinning technique, and the use thereof as new biomaterial for the biomedical and surgical field.

Biomaterials, their preparation by electrospinning and their use in the biomedical and surgical field

The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20&#xb0; C. and at shear rate of D=350 s, comprised between 100 and 250 c Poise and/or a Kinematic viscosity comprised between 99 and 248 cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and/or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and/or platelets contained therein.

Biological material suitable for the therapy of osteoarthrosis, ligament damage and for the treatment of joint disorders

The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.

Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof

Use of hyaluronic acid derivatives for the preparation of biomaterials for the prevention of the formation and the treatment of cutaneous scars, wherein the hyaluronic acid derivatives are optionally combined with pharmacologically or biologically active compounds.

Use of hyaluronic acid derivatives in pharmaceutical preparations and biomaterials for the prevention and treatment of cutaneous scars

The invention concerns the preparation and use of a biocompatible, biocomponent material constituted by: (a) a three-dimensional matrix of hyaluronic acid derivatives witle a structure containing empty spaces; (b) a porous, three-dimensional matrix constituted by a ceramic material; (c) possibly containing pharmacologically or biologically active ingredients.

Grafts for the repair of osteochondral defects

The invention relates to use of a biological material containing cells supported on three-dimensional scaffolds containing at least one hyaluronic acid derivative for the preparation of grafts suitable for application by arthroscopy, and a kit of surgical instruments for implanting said biological material by arthroscopy.

Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy

Growing community of inventors

Thiene, Italy

Lanfranco Callegaro